EP0671951A4 - Humanisierte antikörper, die mit 1-selektine reagieren. - Google Patents

Humanisierte antikörper, die mit 1-selektine reagieren.

Info

Publication number
EP0671951A4
EP0671951A4 EP94903357A EP94903357A EP0671951A4 EP 0671951 A4 EP0671951 A4 EP 0671951A4 EP 94903357 A EP94903357 A EP 94903357A EP 94903357 A EP94903357 A EP 94903357A EP 0671951 A4 EP0671951 A4 EP 0671951A4
Authority
EP
European Patent Office
Prior art keywords
selectin
humanized antibodies
antibodies reactive
reactive
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94903357A
Other languages
English (en)
French (fr)
Other versions
EP0671951A1 (de
Inventor
Man Sung Co
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP0671951A1 publication Critical patent/EP0671951A1/de
Publication of EP0671951A4 publication Critical patent/EP0671951A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP94903357A 1992-12-01 1993-11-30 Humanisierte antikörper, die mit 1-selektine reagieren. Withdrawn EP0671951A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
US983946 1992-12-01
PCT/US1993/011612 WO1994012215A1 (en) 1992-12-01 1993-11-30 Humanized antibodies reactive with l-selectin

Publications (2)

Publication Number Publication Date
EP0671951A1 EP0671951A1 (de) 1995-09-20
EP0671951A4 true EP0671951A4 (de) 1997-05-21

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94903357A Withdrawn EP0671951A4 (de) 1992-12-01 1993-11-30 Humanisierte antikörper, die mit 1-selektine reagieren.

Country Status (12)

Country Link
EP (1) EP0671951A4 (de)
JP (1) JPH08503617A (de)
KR (1) KR100371784B1 (de)
AU (1) AU689090B2 (de)
CA (1) CA2149025A1 (de)
CZ (1) CZ140195A3 (de)
FI (1) FI952658A0 (de)
HU (1) HUT71790A (de)
NO (1) NO952160L (de)
PL (1) PL309249A1 (de)
RU (1) RU2151612C1 (de)
WO (1) WO1994012215A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
JP3604699B2 (ja) * 1995-08-17 2004-12-22 プロテイン デザイン ラブス， インコーポレイティド 多外傷後の多発性臓器不全の防止のための及び体外血液循環後の急性臓器損傷の防止のための抗−セレクチン抗体
DK0951292T3 (da) * 1996-09-27 2007-08-13 Univ Columbia Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
EP4001409A1 (de) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blutkinetik eines antikörpers
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US20110129459A1 (en) 2007-12-05 2011-06-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP2597945B1 (de) * 2010-07-26 2020-07-22 Trianni, Inc. Transgene tiere und verfahren zu ihrer verwendung
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP3222635A1 (de) * 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin-antikörper und verfahren zu ihrer verwendung und identifizierung
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
SG10201913164YA (en) 2011-12-20 2020-03-30 Regeneron Pharma Humanized light chain mice
CA2876172C (en) 2012-06-12 2021-01-19 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (en) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Improved humanized immunoglobulins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (en) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Improved humanized immunoglobulins

Also Published As

Publication number Publication date
WO1994012215A1 (en) 1994-06-09
FI952658A (fi) 1995-05-31
AU689090B2 (en) 1998-03-26
JPH08503617A (ja) 1996-04-23
PL309249A1 (en) 1995-10-02
HU9501564D0 (en) 1995-07-28
HUT71790A (en) 1996-02-28
NO952160L (no) 1995-07-31
NO952160D0 (no) 1995-05-31
AU5732794A (en) 1994-06-22
CA2149025A1 (en) 1994-06-09
FI952658A0 (fi) 1995-05-31
EP0671951A1 (de) 1995-09-20
CZ140195A3 (en) 1996-06-12
RU2151612C1 (ru) 2000-06-27
KR100371784B1 (ko) 2003-07-22

Similar Documents

Publication Publication Date Title
EP0671951A4 (de) Humanisierte antikörper, die mit 1-selektine reagieren.
AU4025193A (en) Humanized C-erbB-2 specific antibodies
HU9601574D0 (en) Humanized antibodies and uses thereof
AU4618193A (en) Humanized antibodies
EP0627932A4 (de) Neuartige antikörperkonstrukte.
EP0604033A3 (de) Dichtungsanordnung.
EP0676966A4 (de) Antikörper gerichtet gegen durch bindung assoziierte epitope.
AU5732694A (en) Humanized antibodies reactive with cd18
EP0578515A3 (de) Humanisierte, monoklonale Antikörper.
GB9412166D0 (en) Retargetting antibodies
GB9313288D0 (en) The super bottle
EP0580859A4 (en) Anti-eda monoclonal antibody
EP0506523A3 (en) Monoclonal antibodies
AU8547291A (en) Monoclonal antibodies against tenascin
GB2246827B (en) Pipe stopper
EP0654532A4 (de) Monoklonale antikörper gegen antimucoglykoprotein.
EP0640621A3 (de) Monoklonaler Antikörper gegen Thrombin.
EP0671924A4 (de) Digitalisartige verbindungen.
ZA931100B (en) A 90K tumor-associated antigen, IR-95.
EP0597211A3 (en) Optical duplexer.
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0668923A4 (de) Monoklonaler antikörper.
ZA928880B (en) Tumor associated monoclonal antibody 88BV59.
IE901956L (en) Monoclonal antibody.
AU4801093A (en) Monoclonal antibodies specific for 3',6'-isold1 ganglioside

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEIN DESIGN LABS, INC.

17Q First examination report despatched

Effective date: 20000407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041126